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The influence of cyclooxygenase-2 (COX-2) overexpression on the development of tumours has been well documented. The
underlying mechanism however has still not been completely elucidated. An escape of proliferating cells from the regulatory influence
of TGF-b for example in the intestine has been discussed as well as a preponderance or prolongation of growth factor stimulation.
The experiments presented here demonstrated that COX-2 transfection of a TGF-b-sensitive cell line abrogates the growth
inhibitory effects of TGF-b. However, analysis of the TGF-b/Smad-signalling pathway clearly revealed that COX-2 overexpression did
not interfere with that. Neither TGF-receptor expression nor Smad phosphorylation and signal transfer into the nucleus were
influenced by COX-2 overexpression. In addition, a TGF-b reporter assay revealed no difference between controls and COX-2-
transfected cells. Thus, the proliferation inhibiting effects must have been well compensated by growth-inducing stimuli. Indications for
this came from experiments showing an induction of TGF-a expression and secretion with a higher and prolonged stimulation of the
ERK 1/2 (p42/44) pathway in COX-2 transfectants. This effect could have been triggered by direct prostaglandin receptor stimulation
or changes in intracellular lipid mediators. An increase in PPAR signalling as proven by a reporter assay is indication for the latter.
Therefore, inhibiting both COX-2 as well as the PPAR and TGF/EGF pathway could be effective in the inhibition of adenoma or even
carcinoma development in the intestine.
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The inducible cyclooxygenase-2 (COX-2) has been shown to be
overexpressed in colorectal cancer and adenomas in humans and
was demonstrated to be a controlling factor in the development of
adenomas in a mouse FAP model (Eberhart et al, 1994; Oshima
et al, 1996). In addition, the regular use of COX inhibitors has been
shown to reduce the relative risk for the development of colon
cancer (Thun et al, 1991; Greenberg et al, 1993; Steinbach et al,
2000; Baron et al, 2003; Sandler et al, 2003). The mechanistic steps,
which link COX-2 overexpression with the generation of a tumour
are however still not fully understood. Possible pathways involve
the escape from regulatory mechanisms as well as interference with
stimulatory effects on cell proliferation. The former comes from
experiments in rat cells showing a reduction of the TGF-b-receptor
expression after COX-2 overexpression (Tsujii and DuBois, 1995).
As TGF-b has a major function as regulator for the cell renewal
in the intestine, this notion gains some support. In addition,
mutations in the TGF-b-receptor have also been associated with
certain tumours in the intestine (Parsons et al, 1995). On the other
hand, mutations are not as common as one would expect, so
regulatory deficits should be much more relevant. To this end, no
functional consequences of COX-2 overexpression in the TGF-b-
pathway have been shown with regard to growth inhibition
or signal transduction. Therefore, we tested the effects of COX-2
overexpression on the growth characteristics of a highly TGF-b-
responsive cell line. In addition, we analysed the TGF-b signalling
pathway and also the influence of COX-2 overexpression on
growth stimulatory mediators.
MATERIALS AND METHODS
Cell culture
The Mv1Lu mink lung epithelial cell line and the human CRC line
HCT-15 were from ATCC (Manassas, VA, USA). Cells were grown
in RPMI 1640 supplemented with 1% glutamine, 1% non-essential
amino acids, 1% MEM vitamins and 10% FCS (all from Invitrogen,
Karlsruhe, Germany).
Transfection
Full-length COX-2 from IL-1-induced human endothelial cells
as well as cPLA2 from LPS stimulated U937 (human monocytic
cell-line) were amplified and cloned into the pcDNA3 expression
vector (Invitrogen, Karlsruhe, Germany). After sequence valida-
tion, plasmid DNA was transfected using FuGene-transfection
reagent according to the protocol of the manufacturer (Roche,
Mannheim, Germany).
TGF-stimulation
Control cells (10
5) as well as COX-2-transfected cells were
stimulated with TGF-b (Strathman Biotech, Hannover, Germany)
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sover 24h. Bromodeoxyuridine (BrdU) was added during the last
4h and cell proliferation measured by a BrdU-assay (Roche,
Mannheim, Germany).
Western blotting
Proteins were separated on a standard 10% polyacrylamide gel,
transferred to nitrocellulose and analysed by incubation with the
specific Ab. Ab used were anti-COX-2 (BD Biosciences, Heidelberg
and Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-c-myc
(Santa Cruz) and anti-(phospho)-p44/42 (ERK1/2; Cell Signalling
Technology, Frankfurt, Germany). For the detection of Smad and
phosphorylated Smad, a polyclonal Ab was used (a generous gift
from P ten Dijke) (Piek et al, 1999). Secondary HRP-coupled Ab as
well as the chemiluminescent substrate (picoSignal) was from
Pierce/Perbio, Bonn.
Reporter assay
The TGF-b reporter construct 3TP-Lux (Wrana et al, 1992) was
transiently transfected using FuGene (Roche) into Mv1Lu as well
as stable COX-2-transfected cells. Twenty-four hours later, cells
were stimulated with TGF-b (1 and 10ngml
1) and lysed after an
additional 24h. Equal amounts of protein were tested for luciferase
and normalised for b-Gal activity (Microlumat, Berthold, Bad
Wildbad; Luciferase/b-Gal reporter assay/Roche). As reporter for
lipid mediators, the DR1-luciferase reporter pBLTK 1 was used
(kindly provided by BU Bauer/Uni Marburg).
RT–PCR
RNA was isolated 24h after COX-2 transfection of cells using the
RNA easy kit according to the manufacturer’s protocol (Quiagen,
Hilden, Germany). The cDNA synthesis and PCR was performed
by standard methods with primers for human TGF-a, HGF and
EGF. The correct size gene-products were densitometrically
analysed after separation on a 1% agarosegel (1D-Software, LTF,
Wasserburg, Germany).
ELISA
TGF-a (R&D Systems, Wiesbaden, Germany) and prostaglandin E2
(PGE2) (correlate EIA, Assay Designs, Ann Arbor, USA) were
measured in the supernatant of cells by commercial ELISAs.
RESULTS
After stabile transfection of Mv1Lu (CCL-COX), the appearance of
the cells changed from an adherent monolayer to a suspension
culture. There was no obvious change in viability or doubling time.
This morphology was stable over several cell passages. Stabile
transfectants express COX-2 as shown by RT–PCR and Western
blotting (Figure 1). COX-2 was functional as shown by an
increased PGE production from 64.9 to 157.7pgml
1 (mean from
one transient/one stabile TF; measured in triplicate) in controls
and transfectants, respectively.
To test the impact of COX-2 expression on the TGF-b-signalling
pathway, parental and transfected cell lines were stimulated with
TGF-b. In accordance with reports from the literature, TGF-b
inhibited the proliferation of Mv1Lu cells in a concentration-
dependent manner. In contrast, COX-2-transfected Mv1Lu cells
were refractory to the inhibitory effects of TGF-b up to a
concentration of 1ng, which totally blocks proliferation in the
original Mv1Lu (Figure 2A). Blocking the cyclooxygenase activity
by aspirin could partly reverse this effect (Figure 2B).
The effects of TGF-b after binding to its receptors are
transmitted via the Smad pathway, where phosphorylated Smad
2/3 enters the nucleus for activation of downstream genes (Heldin
et al, 1997). Protein analysis by Western blotting did not show any
difference in TGF-b type I and II receptor expression between
control and COX-2 expressing cells (Supplementary Figure 1),
which was in contrast to experimental data in a rat epithelial cell
line (Tsujii and DuBois, 1995). Furthermore, the Smad-signalling
pathway was intact. There was no difference in the expression of
Smad 2 and 3 (Supplementary Figure 2) and it was equally
phosphorylated after TGF-b stimulation in controls and COX-2-
transfected cells (Figure 3). In addition, the transfer of the Smad
signal into the nucleus after TGF-b stimulation could be equally
demonstrated by immunofluorescence in control as well as COX-2-
transfected cells (Supplementary Figure 3). The functional effect
could also be shown by an established TGF-b reporter assay
1    2    3
Figure 1 Detection of COX-2 protein by Western blotting. In lane 1,
the parental cell line Mv1Lu was analysed and lanes 2 and 3 are 2 separate
lines transfected with COX-2.
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Figure 2 Growth inhibition curve of Mv1Lu and the COX-2 transfected
line CCL-COX after TGF-b stimulation in (A). Proliferation was tested by
BrdU incorporation. In (B), the effect of aspirin on the growth of TGF-b-
stimulated COX-2-transfected cell lines is plotted in percent of control
growth. Each point was measured in triplicate and the experiment was
repeated at least four times.
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s(Wrana et al, 1992). After co-transfection with the reporter
plasmid, the luciferase activity increased in controls as well as in
COX-2-transfected cells by about eight times. Thus, this reporter
experiment further supports the notion that the TGF-b signal via
Smad is transmitted in the COX-2 transfectants to the same extend
as in controls (Figure 4).
One possibility to counteract the antiproliferative effects of
TGF-b is either blocking the intracellular signal transduction or
upregulating a proliferation signal. The former has been shown to
be mediated by Smad 7, although this effect has mostly been
proven by the inhibition of the reporter. As no interference with
the response of the reporter to TGF-b could be shown after COX-2
co-transfection, this pathway seems to be not effective. So the
overexpression of a proliferation signal could be an alternative
explanation. To test this, we investigated the changes in the
expression of common growth factors for epithelial cells (HGF,
EGF, TGF-a) by RT–PCR after COX-2 transfection. Whereas EGF
and HGF were not induced after COX-2 expression, TGF-a could
be readily detected by PCR after COX-2 transfection (Figure 5). In
addition, the transfectants secreted considerable amounts of TGF-a
into the supernatant (Figure 6). As a consequence, the cells also
had a higher spontaneous phosphorylation of the p44/42 MAPK,
which is a common pathway in growth factor stimulation (Figure 7,
lane 1). To get an idea how the COX-2 signal might be transmitted,
we measured PGE2 concentrations and also tested in a screen
a pathway for lipid signalling. The prostaglandin concentrations
in the medium were in the Mv1Lu cells 64.9pgml
1 in controls
and 157.7pgml
1 in the COX-2 transfected cells, whereas in the
human CRC-line HCT-15, the mean concentration was 100pgml
1
in controls and 450pgml
1 in the COX-2-expressing cells. This
concentration was just below concentrations used to stimulate cells
directly to proliferate. In addition, mRNA for the PGE receptors 2
and 4 was below the detection limit of the RT–PCR. Thus, it seems
more likely that the signal might be transferred by an intracellular
pathway. Indications for this could be seen in a screening for the
reporter assay for lipid mediators. Transfecting a reporter with
binding sites for PPAR/RXR together with COX-2 resulted in an
increase in the luciferase activity compared with controls
(Figure 8). Thus, it seems likely that an endogenous product
generated or affected by the COX-2 overexpression fuelled the
reporter expression.
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Figure 4 Reporter assay using the TGF-b-responsive 3TP-Luc reporter
construct. The mean fold increase over control (measured in triplicate) is
given of cell lysates after normalisation for b-Gal activity. The experiment
was repeated once.
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Figure 5 RT–PCR for TGF-a of cDNA from control (lane 1), COX-2
(lane 2), cPLA (lane 3) and combined COX-2/cPLA (lane 4)-transfected
cells. Amplification was for 30 or 35 cycles and analysed on a 1% agarose
gel stained with ethidium bromide. M, MW marker lane; predicted
amplicon size is 519bp.
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Figure 6 TGF-a concentration (pgml
1) in the supernatant of control
and COX-2-transfected HCT-15 with and without phorbolester (PMA,
1ngml
1) stimulation. Concentration was measured in triplicate. Results
(mean) are from two independent experiments.
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Figure 3 Phosphorylation of Smad after TGF-b stimulation of Mv1Lu
(lane 1–3) and two different COX-2-transfected cell lines (4–6 and 7–9).
Lanes 1, 4 and 7 are cells before TGF-b stimulation, 2, 5 and 8 are 15min
and 3, 6 and 9 are 30min after TGF-b (10ngml
1) stimulation. The lower
band after stimulation corresponds to the phosphorylated Smad (lanes 2, 3,
5, 6, 8 and 9).
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Figure 7 Phosphorylation of ERK1/2 (p42/44) after EGF stimulation in
control (first two rows) and COX-2-transfected HCT-15 (third and fourth
row). First lane is the control without stimulation, next lanes are 5, 10, 15,
30 and 45min after stimulation, respectively. In rows 2 and 4, the
unphosphorylated ERK1/2 (p42/44) serves as loading control. Experiments
with a different cell line (HepG) gave similar results.
COX-2 expression, effect on TGF-b stimulation
GA Enders
1390
British Journal of Cancer (2007) 97(10), 1388–1392 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sDISCUSSION
Overexpression of COX-2 has been associated with the risk for the
development of many different tumours. As one possible outcome
of the COX-2 overexpression, an escape of epithelial cells from
the regulatory influence of TGF-b in the intestine has been
discussed. This has been elegantly shown by the overexpression of
COX-2 in a rat intestinal epithelial cell line, which resulted in a
downregulation of TGF-b-receptor as well as an upregulation of
bcl-2, which may stop growth inhibition by TGF-b as well as lower
apoptosis and finally end in a higher proliferation of epithelial cells
(Tsujii and DuBois, 1995). In contrast to these results, a loss of
TGF-b-receptor expression could not be found after COX-2
overexpression in the experiments presented here. TGF-b, how-
ever, was no longer able to inhibit cell proliferation in Mv1Lu cells,
a common indicator cell line for TGF-b-effects. Therefore, a
mechanism different from the loss of receptor expression must
be effective. The translation of the TGF-b signal into the cell
involves several positive and negative regulators in the cytosol. The
phosphorylation of Smad proteins and their translocation into
the nucleus are indicative for an effective transfer of the signal.
This pathway, however, was unaffected in Mv1Lu cells over-
expressing COX-2. So how was the escape from inhibition
mediated? Activating of inhibitors of the Smad pathway and Smad
or even TGF-b-independent mechanisms might be responsible for
the proliferation of the cells in the presence of TGF-b after COX-2
overexpression.
Direct inhibitory molecules, which interfere with the TGF-
signalling pathway, have been described including Sno or Ski or
more recently Akt (Conery et al, 2004; Remy et al, 2004). These
molecules, however, act only in concert with Smad, for example,
are bound to Smad and inhibit Smad translocation, which seems
not to be affected in the experiments presented here. After TGF-b
stimulation, the signal can be blocked by inhibitory factors like
Smad 7 (Hayashi et al, 1997). The inhibitory effect of this pathway
has been similarly proven by a reduction of the signal response of a
reporter construct. As in the experiments presented here, COX-2
transfectants still respond to TGF-b with an increase of the
reporter signal, direct inhibition of the Smad pathway seems to be
unlikely.
The intracellular signalling of TGF-b consists of two well-
defined pathways: one that includes the Smad signalling as
outlined above (Massague et al, 2000) and a Smad-independent
pathway (Derynck and Zhang, 2003). As the experiments show all
activation steps in the Smad pathway even in the cells over-
expressing COX-2, a Smad-independent pathway seems to be
responsible for the escape of the cells from TGF-b-induced growth
inhibition. There have been reports of crosstalk between the TGF-b
signalling and an activation of receptor tyrosin kinases. The latter
transmit quite often the signal of growth hormones and induce cell
proliferation (Grunert et al, 2003) even in the presence of an
antiproliferative milieu. In this regard, it has been postulated that
the overexpression of an oncogene may override the TGF-b effects
(Siegel and Massague, 2003). From this, it is an interesting finding
that the COX-2-transfected cells display higher TGF-a expression/
secretion and a higher activation of the ERK-pathway. The
activation of the ERK pathway could be explained by the
transactivation of the EGF receptor as has been shown for the
stimulation with PGE2 (Pai et al, 2002). EGF-receptor activation
leads to a signalling by the MAPK, which has been suggested to
antagonise the TGF-b pathway (Lo et al, 2001) and induce the
oncogene myc-expression (Alarcon-Vargas and Ronai, 2004),
which may bypass the growth inhibition. In human cholangio-
carcinoma cells, growth and invasive properties could be
stimulated by PGE2/EP1 receptor mediated EGF-receptor activa-
tion (Han and Wu, 2005). However, although PGE could be found
to be much higher in COX-2-transfected cells, it never reached the
concentration used to induce transactivation. So a direct effect of
the overexpressed TGF-a on the EGF-receptor seems more likely.
An interrelation between COX-2 and growth factors has been
shown before for TGF-a and amphiregulin (Coffey et al, 1997; Shao
et al, 2004). In this regard, it is interesting that TGF-a-stimulated
cells have been used for the isolation and cloning of COX-2
(DuBois et al, 1994) and shows the close interrelation between both
systems. One must make the point, however, that the polarised
secretion of the TGF-a together with the localised expression of the
EGF-receptor may impede the growth stimulation in polarised
epithelial cells. This may be changed dramatically in hyperproli-
ferating cells as in adenomas or less differentiated cells, which may
lose polarity (Huang et al, 1995). On the other hand, TGF-b has
been shown to induce TGF-a expression with the consequence of
EGF-receptor activation (Vinals and Pouyssegur, 2001) and an
increase in c-myc oncogene expression (Skouteris and McMena-
min, 1992), as we could demonstrate in the transfected cells here
(Supplementary Figure 4). Although direct prostaglandin effects
via exogenous receptor activation are a good explanation,
endogenously produced lipid mediators may also mediate effects.
In this regard, non-enzymatic products of the prostaglandin
pathway like PGJ as well as arachidonic acid have been shown to
trigger important signalling via PPAR activation (Dobbie et al,
2002; Laurora et al, 2003). The stimulation of a PPAR-responsive
element in the DR-reporter after COX-2 overexpression demon-
strates this pathway. There are reports of inhibitory effects of
PPAR-g on the TGF/Smad pathway and also on the block of TGF-
b-induced mitoinhibition (Han et al, 2004; Zhao et al, 2006).
Therefore, the direct PGE as well as the PPAR-mediated effects can
explain the effects of COX-2 overexpression on the TGF-b
pathway. This could, in addition to the reported loss of TGF-b
receptor, explain how epithelial cells can escape from the growth
regulation in the intestine ultimately leading to hyperproliferation
and the formation of adenomas, which are prerequisite for
carcinoma formation. Therefore, not only the inhibition of the
cyclooxygenase is a good strategy for treating patients at risk but
also a combination with PPAR inhibitor may boost the therapeutic
repertoire.
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